Field of Science

Biotechnology. Misunderstood.

David Kroll, veteran science blogger, educator and Director of Science Communications at the NC Museum of Natural History is having a hard time convincing someone of the importance of biotechnology and of communicating it to the public. As a scientist working at a biotech company myself, this seemed to be of particular interest to me and it also turned out to be particularly disconcerting. In this case David's correspondent happens to be Ms. Laura Combs, a former state environmental agency employee writing at a blog that seems to discuss diverse topics connected with medicine and the environment. Unfortunately that's not precluded her from inventing some rather strange ideas about the definitions and scope of biotechnology.

Ms. Combs seems to be an engaged citizen who genuinely appreciates the work done by the NCMNS, and that makes her response even more perplexing. The incident started innocently enough with the NCMNS organizing a 'Biotechnology Day' that showcased biotechnology research for the public. I believe this is an exceedingly important endeavor that should be encouraged, especially in the face of the growing importance of biotechnology and genomics in our lives. The presentations were split evenly between people from industry, academia and the agricultural sector; again, an entirely fair split since these three sectors are where the majority of biotech research takes place. 

Unfortunately the inclusion of industry in the museum's events sparked a backlash from Ms. Combs, which resulted in a lengthy correspondence with David and others at the museum. What left me the most nonplussed was Ms. Combs's definition of biotechnology as something antagonistic to the natural world and generally malevolent to humanity. Biotechnology, according to Ms. Combs, was not compatible with the "natural science" that the museum claimed to promote. Leaving aside the fact that the public dissemination of science should include all of science and not just "natural" science, unfortunately this seems to be a common foundational misunderstanding on the part of biotech opponents and it seems to ignore a lot of things, including a starting point in Darwin's great work "The Origin of Species".

Darwin kicked off his thoughts on natural selection in the first chapter of his book by reminding us of the artificial selection done on domestic animals and agricultural plants for hundreds of centuries. Yes, all these people who were practicing artificial selection were doing 'biotechnology' even if they had no knowledge of genes. But the overarching point that Darwin was getting at was that nature also practices biotechnology in the form of natural selection, and has in fact been doing so since the origin of life. This is probably the biggest mistake that biotech opponents make, to think of biotech as a wholly human invention. All of natural selection that involves the selective retention and manipulation of genes and phenotypes is biotechnology. In addition as David notes in his detailed reply, horizontal genetic transfer has been one of the key driving forces of evolution. Again, biotechnology. And perhaps Ms. Combs would like to know that about 8% of our genome consists of genes from retroviruses that were inserted during evolution. Thus, viruses were doing biotech with us long before we started doing biotech with them. The fact is that gene transfer and manipulation have been natural processes that we have very recently started to exploit. That also leads directly to Ms. Combs's criticism about GM foods. She is right in insisting that presentations regarding the benefits of GM foods need to be balanced with their possible side-effects, but she also seems to fall prey to a more basic and flawed belief that GM foods are fundamentally a new, man-made creature in the list of biological species. They are not. Nature has been trying out GM foods for millennia.

As a biotechnology scientist myself I was particularly distressed by the response, since I happen to study a particular form of biotechnology in my research that would not follow Ms. Combs's definition. My company uses the specific base pairing properties of DNA - one of its most amazing and fundamental features - to make drugs for cancer, psoriasis and other disorders. My research which has been pioneered by an academic lab has nothing to do with GM foods, I don't work for Big Pharma, and I am not manipulating anyone's genes. I am using entirely natural processes to help me find drugs for diseases which very palpably affect millions of people every year. In my case, nature is the entity that's allowing me to do biotechnology and I find this fact fascinating. I find it hard to see how Ms. Combs could be against the kind of research I am doing, but the major point as pointed out David is that biotech goes far beyond GM and into many areas of science like detergent manufacture, biodefense and health supplements. What I am doing is just one of its myriad manifestations.

Unfortunately, this kind of valid debate about the definition or pros and cons of biotechnology is undermined by Ms. Combs insinuations about the penalties paid by Big Pharma and their unethical practices. Ms. Combs seems to erect a classic straw man and points out the huge fines paid by Monsanto, Pfizer, Bayer and others for false labeling, bribes to doctors and other transgressions - and nobody's supporting these practices - but what on earth do these fines have to do with the scientific evidence for or against GM foods? This listing of pharmaceutical evils is completely tangential to the science of GM foods and smells suspiciously of guilt-by-association. In her emphasis on including equal time for critics of biotech, she also suggests the name of people who seem to be bonafide supporters of the vaccine-autism link. It's one thing to have a balanced debate, quite another to give voice to critics whose arguments are chiefly fueled by emotion and incomplete evidence rather than reason. 

Finally, she is not impressed by the inclusion of academic presentations in the museum's events because she says that universities "receive significant funds from industry to support biotechnology research". That part is especially amusing since the biotechnology revolution was launched almost entirely by academic scientists like Fred Sanger, Paul Berg and Hamilton Smith as an offshoot of basic, curiosity-driven research about the natural world. And a moment's research would have convinced Ms. Combs that the scientific underpinnings of biotechnology have been almost entirely taxpayer funded...by taxpayers like herself.

I am not singling out Ms. Combs for her objections and I do respect her general support of the museum and her regular visits to it. But she seems to have started a minor campaign on her blog to discredit the museum's attempts to help the public to understand biotechnology. This is disappointing. David has responded in as much detail as possible to her emails, and anyone who knows him would be aware of the tremendous and admirable work he has done for years in support of the public understanding of science; it would sound ludicrous for those of us who know his work to hear the allegation that he does not appreciate the merits of a balanced scientific debate. 

What I would like to say to Ms. Combs is this; biotechnology has been with us since the origins of life, and recombinant DNA is only the latest incarnation of a process that started billions of years ago. To say that biotechnology is at odds with the natural world is to completely ignore the biotechnology that nature has always practiced and to proclaim that man is not a part of nature. But more importantly, whether you like it or not, biotechnology and genomics are poised to enter the public discourse in ways that we can't even imagine yet. Genomic medicine is on the threshold of impacting public health and policy in a big way, and it promises to create new drugs for major disease and new diagnostics that will allow us to detect diseases like cancer earlier. Like other scientific developments, discoveries in the next few decades will make us confront novel social and moral issues. It's all biotechnology, knowledge that's based on the fundamental workings of the biological universe, and it will be upon us very soon. And as recent progress demonstrates, it will inevitably be developed by both academia and industry. 

Would it have unintended consequences? Of course it would, like every other technology. But that is precisely the reason to publicize it as widely as possible, to make sure that the public is aware of the most cutting-edge research in the field. If you are suspicious of biotechnology, then you should be the first one to make sure that museums all around the country organize biotechnology days to discuss, debate and present. About the worst thing you can do about a topic which you don't trust is to advocate that it should not be discussed in a public forum.

2012 Nobel Prizes


Predicting the Nobel Prizes gets easier every year ((I said predicting, not getting your predictions right) since there’s very little you can add in the previous year’s list, although there are a few changes; the Plucky Palladists can now happily be struck off the list. As before, I am dividing categories into ‘easy’, and ‘difficult’ and assigning pros and cons to every prediction. This is a revised and updated version of my list from last year. Paul has already kicked off the predictions.

The easy ones are those regarding discoveries whose importance is (now) ‘obvious’; these discoveries inevitably make it to lists everywhere each year and the palladists clearly fell into this category. The difficult predictions would either be discoveries which have been predicted by few others or ones that that are ‘non-obvious’. But what exactly is a discovery of ‘non-obvious’ importance? Well, one of the criteria in my mind for a ‘non-obvious’ Nobel Prize is one that is awarded to an individual for general achievements in a field rather than for specific discoveries, much like the lifetime achievement Academy Awards given out to men and women with canes. Such predictions are somewhat harder to make simply because fields are honored by prizes much less frequently than specific discoveries.

When predicting the Nobel prize it’s also prudent to be cognizant of discoveries whose recognition makes you go “Of course! That’s obvious”. Prizes for the charge-coupled device (CCD) (2009) integrated chip (2000) and in-vitro fertilization (2010) fall into this category.

Anyway, here's the N-list for chemistry:

Single-molecule spectroscopy (Easy)
Pros: The field has obviously matured and is now a powerful tool for exploring everything from nanoparticles to DNA. It’s been touted as a candidate for years. The frontrunners seem to be W E Moerner and M Orrit, although Richard Zare has also been floated often.
Cons: The only con I can think of is that the field might yet be too new for a prize.

Lithium-ion batteries (Moderately easy): Used in almost every kind of consumer electronics, lithium-ion batteries are also touted as the best battery alternative to fossil fuels. A great account is provided in Seth Fletcher’s “Bottled Lightning”. From what I have read in that book and other sources, John Goodenough, Stanley Whittingham and Akira Yoshino seem to be the top candidates, although others have also made important contributions and it may be hard to divide up the credit.


Computational chemistry and biochemistry (Difficult):

Pros: Computational chemistry as a field has not been recognized since 1998 so the time seems due. One obvious candidate would be Martin Karplus. Another would be Norman Allinger, the pioneer of molecular mechanics.

Cons: This would definitely be a lifetime achievement award. Karplus did do the first MD simulation of a protein ever but that by itself wouldn’t command a Nobel Prize. The other question is regarding what field exactly the prize would honor. If it’s specifically applications to biochemistry, then Karplus alone would probably suffice. But if the prize is for computational methods and applications in general, then others would also have to be considered, most notably Allinger but perhaps also Ken Houk who has been foremost in applying such methods to organic chemistry. Another interesting candidate is David Baker whose program Rosetta has really produced some fantastic results in predicting protein structure and folding. It even spawned a cool game. But the field is probably too new for a prize and would have to be further validated; at some point I do see a prize for biomolecular simulation.

Chemical genetics (Easy)
Another favorite for years, with Stuart Schreiber and Peter Schultz being touted as leading candidates.Pros: The general field has had a significant impact on basic and applied scienceCons: This again would be more of a lifetime achievement award which is rare. Plus, there are several individuals in recent years (Cravatt, Bertozzi, Shokat) who have contributed to the field. It may make some sense to award Schreiber a ‘pioneer’ award for raising ‘awareness’ but that’s sure going to make at least some people unhappy. Also, a prize for chemical biology might be yet another one whose time has just passed).


Electron transfer in biological systems (Easy)
Pros: Another field which has matured and has been well-validated. Gray and Bard seem to be leading candidates.

NMR (Difficult): It’s been a while since Kurt Wuthrich won the prize for NMR. But it’s been even longer since a prize was awarded for methodological developments in the field (Richard Ernst). I don’t know enough about the field to know who the top contenders would be, but Ad Bax and Alexander Pines seem to have really made pioneering contributions. Pines especially helped launch the field of solid-state NMR which as a field certainly seems to deserve a Nobel at some point.

Among other fields, I don’t really see a prize for the long lionized birth pill and Carl Djerassi; although we might yet be surprised, the time just seems to have passed. Then there are fields which seem too immature for the prize; among these are molecular machines (Stoddart et al.) and solar cells (Gratzel). One promising candidate is Krzysztof Matyjaszewski whose work in ATRP has had a pronounced impact on the way polymers are made; this would neatly fit into the Nobel Prize’s requirement for work that is both fundamental and has “benefited humanity”.

MEDICINE/CHEMISTRY:


Nuclear receptors (Easy)
Pros: The importance of these proteins is unquestioned. I worked a little on NRs during my postdoc and remember being awed by the sheer diversity and ubiquity of these molecules in mediating key physiological functions. In addition they are already robust drug targets, with drugs like tamoxifen that hit the estrogen receptor making hundreds of millions of dollars. Most predictors seem to converge on the names of Chambon, Jensen and Evans and this prediction is definitely at the top of my list.

Chaperones: (Easy)

Arthur Horwich and Franz-Ulrich Hartl just won this year’s Lasker Award for their discovery of chaperones. Their names have been high on the list for some time now.
Pros: Clearly important. Chaperones are not only important for studying protein folding on a basic level but in the last few years the malfunctioning of chaperones such as heat-shock proteins has been shown to be very relevant to diseases like cancer.

Cons: Too early? Probably not.

Statins (Difficult)

Akira Endo’s name does not seem to have been discussed much. Endo discovered the first statin. Although this particular compound was not a blockbuster drug, since then statins have revolutionized the treatment of heart disease.
Pros: The “importance” as described in Nobel’s will is obvious since statins have become the best-selling drugs in history. It also might be a nice statement to award the prize to the discovery of a drug for a change. Who knows, it might even boost the image of a much maligned pharmaceutical industry...
Cons: The committee is not really known for awarding actual drug discovery. Precedents like Alexander Fleming (antibiotics), James Black (beta blockers, antiulcer drugs) and Gertrude Elion (immunosuppresants, anticancer agents) exist but are far and few in between. On the other hand this fact might make a prize for drug discovery overdue.

Drug delivery (Difficult): A lot of people are pointing to Robert Langer for his undoubtedly prolific and key contributions to drug delivery. The field as a whole has not been recognized yet so the time may be ripe; from my own understanding of his contributions, Langer seems to me more of an all-rounder, although it may not be too late to single out some of his earlier discoveries, such as the first demonstration of the delivery of high molecular weight polymer drugs.



Cancer genetics (Easy): Clearly a very important and cutting-edge field. We still don’t know how much of an impact genomic approaches will ultimately have on cancer therapy since the paradigm is clearly evolving, but any history of the field will have to include Robert Weinberg and Bert Vogelstein. Vogelstein discovered p53, the “guardian of the genome” while Weinberg discovered the first oncogenes. In addition both men have also been prominent influences on the field as a whole. Given both the pure and applied importance of their work, their discoveries should fit the Nobel committee’s preferences like a glove.


Genomics (Difficult)
A lot of people say that Venter should get the prize, but it’s not clear exactly for what. Not for the human genome, which others would deserve too. If a prize was to be given out for synthetic biology, it’s almost certainly premature. Venter’s synthetic organisms from last year may rule the world, but for now we humans still prevail. On the other hand, a possible prize for genomics may rope in people like Carruthers and Hood who pioneered methods for DNA synthesis.

DNA fingerprinting (Easy):
Now this seems to me to be very much a field from the “obvious” category. The impact of DNA fingerprinting and Western and Southern Blots on pure and applied science- everything from discovering new drugs to hunting down serial killers (and exonerating wrongly convicted ones; for instance check out this great article by Carmen Drahl in C&EN)- is at least as big as the prizeworthy PCR. I think the committee would be doing itself a favor by honoring Jeffreys, Stark, Burnette and Southern. And while we are on DNA, I think it’s also worth throwing in Marvin Caruthers whose technique for DNA synthesis really transformed the field. In fact it would be nice to award a dual kind of prize for DNA- for both synthesis and diagnosis.

Cons: Picking three might be tricky.

Stem Cells (Easy)

This seems to be yet another favorite. McCulloch and Till are often listed. Unfortunately McCullough died earlier this year so it would be a little unfair to award just Till. However such a thing is not unprecedented. For example, the psychologist Daniel Kahneman shared the 2002 Economics Nobel Prize with Vernon L. Smith. Left out was his long-time collaborator Amos Tversky who had died in the 90s; it’s pretty much regarded as a given that Tversky would have shared the prize had he been alive.

Pros: Surely one of the most important biological discoveries of the last 50 years, promising fascinating advances in human health and disease.

Cons: Politically controversial (although we hope the committee can rise above this). Plus, a 2007 Nobel was awarded for work on embryonic stem cells using gene targeting strategies so there’s a recent precedent.

Membrane vesicle trafficking (Easy)

Pros: Clearly important. The last trafficking/transport prize was given out in 1999 (Blobel) so another one is due and Rothman and Schekman seem to be the most likely canidates. Plus, they have already won the Lasker Award which in the past has been a good indicator of the Nobel.

GPCR structures (Difficult)

When the latest GPCR structure (the first one of a GPCR bound to a G protein) came out I remember remarking that Kobilka, Stevens and Palczewski are probably up for a Nobel Prize sometime. In the last two years I have become convinced that they deserve it. Palczewski solved the first structure of rhodopsin and Stevens and Kobilka have been churning out structure after important structure over the last decade, including the first structure of an active receptor along with several medicinally important ones including the dopamine D3 and CXCR4 receptors. Kobilka topped it off early this year with another tour-de-force, the structure of the beta adrenergic receptor bound to its G-protein. The implications of these structures are far-reaching but the results are already being used by both pure and applied scientists to better understand GPCR function and design GPCR-targeting drugs.

Pros: GPCR’s are clearly important for basic and applied science, especially drug discovery where 30% of drugs already target these proteins.


Cons: Perhaps too early.

PHYSICS

I think it’s high time Anton Zeilinger, John Clauser and Alain Aspect got it for bringing the unbelievably weird phenomenon of quantum entanglement to the masses. Zeilinger’s book “Dance of the Photons” presents an informative and revealing account of this work



I have also always wondered whether non-linear dynamics and chaos deserves a prize. The proliferation and importance of the field certainly seems to warrant one; the problem is that there are way too many deserving recipients (and Mandelbrot is dead). Among the pioneers, Feigenbaum, May and Yorke come to mind easily.

Drug discovery 2.0: Rise of the biologics? Not so fast

Along with ominous drumbeats heralding the decline of the pharmaceutical industry, another recurring lament that we hear these days is about the decline of small molecules and the rise of biologics like antibodies and other proteins. The last decade has seen several successful antibody drugs, especially against cancer. Based on this success the prevailing wisdom (which does not tire of making its presence known) seems to suggest that traditional small molecule drugs are being shown the door even as biologics with their much higher specificities and lack of side effects are being welcomed in.

Not so fast. A rather refreshing opinion piece from a B. Meunier from CNRS in this week's Angewandte Chemie makes a strong case that rumors of small molecules' deaths are grossly exaggerated. Along the way Meunier also takes a swipe at what he considers to be Europe's stifling innovation culture; his point is that since the "new" model of pharmaceutical research is going to entail "Big" Pharma licensing compounds in from small companies, the model can only thrive in countries where a healthy startup culture already exists. And Meunier does not see European countries steering that boat. Of course he does not discuss the rather baleful VC funding environment in the US, but that's a tale of woe for another article.


Meunier points out some rather obvious but important problems with biologics that their upbeat proponents sometimes cheerfully dismiss. Foremost is the price tag, with the minimum cost of a monoclonal antibody being in the tens of thousands of dollars, and many costing hundreds of thousands. Secondly, antibodies have had their biggest success against cancer where the high cost has to be balanced against the terminal nature of the disease, the little time that patients have and the possibility of complete remission. Contrast that with chronic diseases like diabetes, heart disease and arthritis where people have to be on therapies for years. It would be prohibitively expensive to consider an antibody treatment in such cases unless there's some new revolutionary way to lower costs of production; needless to say such breakthroughs are not visible around the corner. 


Thirdly, antibodies and protein therapeutics have obvious clinical limitations; they cannot cross the blood brain barrier and are therefore of little use against neurodegenerative disorders like Alzheimer's, and they can mostly attach only to extracellular targets and therefore may be useless for targeting intracellular proteins. There's also the perpetually inconvenient fact that they have to be injected, another stumbling block on the way to using them against chronic diseases. Finally, Meunier thinks that the whole economic basis for biologics, namely the belief that generics will take a very long time to hit the market because of the production challenges, may well be refuted sooner than we think. If there's one lesson we have learnt from the history of innovation, from the development of paper to the atomic bomb, it's that other countries don't lack smart innovators, and given enough time they will always come up with novel ideas to speed up production and lower costs. Putting all your eggs in the "It will be decades before India and China can come up with generic versions of biologics" basket is a dangerous strategy.


Ultimately small molecules have one thing going for them; they have worked ever since the dawn of drug discovery and they continue to be robust, versatile and easy to make. As Meunier points out, occasional competitors like oligonucleotide therapies have largely bit the dust. And of course the sheer number of ways in which you can combine six elements to build a drug is literally astronomical; we have barely scratched the surface of chemical diversity and there's still myriad scaffolds to plumb. Meunier's message is thus to keep up the good work with small molecules, employing the whole toolkit of chemistry comprising not just synthesis but analysis and modeling. Biologics may stridently stake out certain areas of the drug kingdom, but small molecules will continue to rule for the foreseeable future.


Latest Scientific American posts

Not to beat a dead Sprague Dawley rat, but I have another post on Sci Am comparing airplane and drug design, this time discussing some of the actual complexity of protein-drug binding.

On occasion of a special "Beginnings" blog festival on multiple sites, I make a case for why the Origin of Life is chemistry's grand question.

And here's some thoughts on the chemistry of Curiosity.

Again, drug design and airplane design are not the same

A while back I had a post about an article that compared airplane design to drug design. I discussed the challenges in drug design compared to airplane design and why the former is much less predictable than the latter, the short answer being "biological complexity".

Now the analogy surfaces again in a different context. C & EN has an interview with Kiran Mazumdar-Shaw, CEO of India's largest biopharmaceutical company Biocon. Shaw is an accomplished woman who does not hold back when she laments the current depressing state of drug development. I think many of us would commiserate with her disappointment at the increasing regulatory hurdles that new drugs have to face. But at one point she says something that I don't quite agree with:

Mazumdar-Shaw dismisses the argument that drugs create a public safety imperative mandating stricter oversight than many other regulated products. “So you think passenger safety is any less important than patient safety?” she asked. Yet aircraft makers don’t face a 12-year, all-or-nothing proposition when designing, developing, and commercializing an airplane. Nor, she added, does Boeing have to prove that it is making something fundamentally different than what Airbus already has on the market.

To which my counter-question would be, "What do you think is the probability of unforeseen problems showing up in aircraft design compared to drug design"? I see a rather clear flaw in the analogy; aircraft design is not as tightly regulated because most aircraft work as designed and the attrition rate in their development is quite low. The number of failures in aircraft development pale in comparison with the number of Phase II failures in drug development. In fact as the article quoted in my previous post described, these days you can almost completely simulate an aircraft on a computer. Regulatory agencies can thus be much more confident and insouciant about approving a new airplane.

This is far from the case for drugs. First of all there is no clear path to a drug's development and in the initial stages most people don't have a clue as to what the final product is going to look like. But more importantly, designing drugs is just so much riskier than designing aircraft that regulatory agencies have to be more circumspect. How many times do drugs show all kinds of side-effects which would never have been predicted at the beginning? How many times do drugs show side-effects that would not even have been imagined at the beginning? It's this almost complete lack of prediction driven by the sheer complexities of biology that distinguishes drugs from airplanes.

In another part of the interview Mazumdar-Shaw voices her impatience with regulators' recalcitrance to adopt new technologies. The example she gives is of Hawk-Eye, a computer that tracks a tennis ball's movement and makes it easier to call out the result of a disputed bounce. Just like sports authorities are reluctant to use these technologies to override the flaws in human judgement, Mazumdar-Shaw thinks regulators are reluctant to use new technologies to overcome the limitations of human judgement. The point is not irrelevant but the truth is that decision making in drug development is far more complex than decision making in tennis tournaments. For Hawk-Eye to track tennis balls is a simple matter of physics, and it can do this with high accuracy. Contrast this with drug development where the "event" to be analyzed is not the bounce of a ball but the efficacy of a drug in a large clinical trial as assessed by a variety of complex statistical measures. In addition, approving a drug is inherently more subjective, being based on efficacies of existing therapies, the exact numerical superiority of the extra benefits, cost and patient populations. Good luck writing a computer problem that could possibly assess this morass of sometimes conflicting information and reach an informed judgement.

I think many of us are frustrated with the increasing regulatory hurdles that new drugs face and we all wish that the process was smoother. Personally I don't think that the FDA's systems for assessing risks is as finely attuned to potential benefits as it should be. But I don't find myself following Mazumdar-Shaw in advocating for drug approvals that are as easy as aircraft approvals. The former is science and engineering. The latter is science with a healthy dose of intuition and art. And some black magic.

Protein-ligand crystal structures: WYSI(N)WYG

Crystal structures of proteins bound to small molecules have become ubiquitous in drug discovery. These structures are routinely used for docking, homology modeling and lead optimization. Yet as several authors have shown over the years, many of these structures can hide flaws that don't become apparent until they are actually revealed through analysis. Worse still, there may be flaws that never become apparent because nobody takes the trouble to look at the original data.

A recent paper from the group at OpenEye has a pretty useful analysis of flaws in crystal structures. They carry on a tradition most prominently exemplified by Gerard Kleywegt at Uppsala. The authors describe common metrics used for picking crystal structures from the PDB and demonstrate their limitations. They propose new metrics to remedy the problems with these parameters. And they use these metrics to analyze about 700 crystal structures used in structure-based drug design and software validation and find out that only about 120 structures or so pass the rigorous criteria used for distinguishing good structures from bad ones.

The most important general message in the article is about the difference between accuracy and completeness of data, and the caveat that any structure on a computer screen is a model and not reality. Even very accurate looking data may be incomplete and this flaw is often neglected by modelers and medicinal chemists when picking crystal structures. For instance, the resolution of a protein structure is often used as a criterion for selecting one among many structures of the same protein from the PDB. Yet the resolution only tells you how far apart atoms can be distinguished from each other. It does not tell you if the data is complete to begin with. So for instance, a crystallographer can acquire only 80% of the theoretically maximum possible data and present it with a resolution of 1.5 A, in which case the structure is clearly incomplete and possibly flawed for use in structure-based drug design. Another important metric is the R-free factor which is obtained by omitting certain parts of the data and refitting the rest to the model. A difference between R-free and the R-factor (a factor denoting the original difference between the full set of data and the model) of more than 0.45 for a structure with resolution 3.5 A or more is a red flag.

The OpenEye authors instead talk about a variety of measures that provide much better information about the fidelity of the data than resolution. The true measure of the data is of course the actual electron density. Any structure that is seen on the computer screen results from the fitting of a model to this electron density. While proteins are often fit fairly well to the density, the placement of ligands is often more ambiguous, partly because protein crystallographers are not always interested in the small molecules. The paper documents several examples of electron density that was either not fit or incorrectly fit by ligand atoms. In some cases sparse or even non-existent density was fit by guesswork, as in the illustration above. All these badly fit atoms show up in the final structure but only an expert would know this. The only way to overcome these problems is to take a look at the original electron density, which is unfortunately a task that most medicinal chemists and modelers are ill equipped for.

The worst problem with these crystal structures is that because they look so accurate and nice on a computer screen, they may fall into Donald Rumsfeld's category of "unknown unknowns". But even with "known unknowns" the picture is a disturbing one. When the authors apply all their filters and metrics to a set of 728 protein-ligand structures frequently used in benchmarking docking programs and in actual structure-based drug design projects, they find that only 17% or so (121) of the structures make it through. They collect these structures together and call the resulting database Iridium which can be downloaded from their website. But the failure of the 580 or so common structures used by leading software vendors and pharmaceutical companies to pass important filters leaves you wondering how many resources we may have wasted by using them and how much uncertainty is out there. 

Something to think about, especially when considering the 50,000 or so protein structures in the PDB. What you see may not be what you get.

Gene duplication and molecular promiscuity

Head over to the Scientific American blog for a post that discusses a recent article suggesting a link between gene duplication and the promiscuity of enzymes involved in secondary metabolism in plants. Since gene duplication frees up one copy of the gene to "experiment", it can potentially accumulate mutations that confer the ability to bind and process more than one substrate. We should partly thank gene duplication for giving us many secondary metabolites which are used as drugs (both recreational and non-recreational), flavors and food products.